^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    JAK inhibitor

    Related drugs:
    17h
    TQ05105-Ⅱ-01: A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis (clinicaltrials.gov)
    P2, N=107, Active, not recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recruiting --> Active, not recruiting | Trial completion date: Sep 2023 --> Feb 2026
    Enrollment closed • Trial completion date
    |
    JAK2 (Janus kinase 2)
    |
    hydroxyurea • rovadicitinib (TQ05105)
    1d
    Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis (clinicaltrials.gov)
    P2, N=20, Recruiting, Fred Hutchinson Cancer Center | Suspended --> Recruiting
    Enrollment open
    |
    cyclophosphamide • melphalan • fludarabine IV • Inrebic (fedratinib)
    3d
    Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease (clinicaltrials.gov)
    P2, N=60, Recruiting, National Institute of Dental and Craniofacial Research (NIDCR)
    New P2 trial
    |
    tofacitinib
    6d
    A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets (clinicaltrials.gov)
    P1, N=40, Completed, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Completed
    Trial completion
    |
    itraconazole • rifampicin • rovadicitinib (TQ05105)
    9d
    Comparison Between JAK Inhibitors and Traditional Treatment of Rheumatoid Arthritis (clinicaltrials.gov)
    P=N/A, N=72, Not yet recruiting, Assiut University
    New trial
    10d
    Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=39, Recruiting, University of Michigan Rogel Cancer Center | Trial completion date: Oct 2029 --> Jan 2030 | Trial primary completion date: Oct 2027 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    Xtandi (enzalutamide) • Jakafi (ruxolitinib)
    10d
    A Study of TQ05105 Tablets in Subjects With Glucocorticoid-Refractory Acute Graft-Versus-Host Disease (aGVHD) (clinicaltrials.gov)
    P1/2, N=13, Completed, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Active, not recruiting --> Completed
    Trial completion
    |
    rovadicitinib (TQ05105)
    15d
    A Study of TQ05105 in Patients With Chronic Graft Versus Host Disease (clinicaltrials.gov)
    P1/2, N=45, Active, not recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Trial completion date: Dec 2024 --> Dec 2026
    Trial completion date
    |
    rovadicitinib (TQ05105)
    16d
    A Study to Investigate the Safety, Tolerability and Preliminary Efficacy of NGI226 Microparticles in Patients With Achilles Tendinopathy (clinicaltrials.gov)
    P2, N=45, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting
    Enrollment closed
    16d
    A Phase I Study Evaluating the Safety, Tolerability, and Pharmacokinetics of VVN432 Nasal Spray (clinicaltrials.gov)
    P1, N=60, Recruiting, VivaVision Biotech, Inc
    New P1 trial
    20d
    ABX464-103: Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis (clinicaltrials.gov)
    P2, N=355, Completed, Abivax S.A. | Phase classification: P2b --> P2 | N=254 --> 355
    Phase classification • Enrollment change
    |
    mercaptopurine
    24d
    HEMA-MED: A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors (clinicaltrials.gov)
    P1/2, N=26, Recruiting, iOnctura | Initiation date: May 2025 --> Nov 2025
    Trial initiation date
    |
    Jakafi (ruxolitinib) • roginolisib (IOA-244)